| Name | Title | Contact Details |
|---|---|---|
Lauryn Bailey |
Vice President, Global Marketing, Strategy, and Product Management | Profile |
Emmet Welch |
Senior Director, R&D | Profile |
Sandy Ottensmann |
Vice President, Global Marketing & Product Management | Profile |
Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension.
Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Our lead drug candidate, momelotinib, is a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing a range of meaningful anemia benefits, including eliminating or reducing the need for frequent blood transfusions, as well as achieving substantive spleen and constitutional symptom control. We are also advancing SRA737 and SRA141. SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). We are pursuing an innovative development plan for SRA737, which is currently being evaluated in two Phase 1/2 clinical trials in patients with advanced cancer. SRA737-01 is intended to evaluate SRA737`s potential to induce synthetic lethality as monotherapy, while SRA737-02 is intended to evaluate the combination of SRA737 potentiated by subtherapeutic, low dose gemcitabine. Concurrently, we are conducting preclinical research evaluating SRA737 in combination with other DDR-targeted agents, including PARP inhibitors, as well as with immuno-oncology therapeutics, that may guide a potential next wave of clinical development for our asset, possibly further broadening its therapeutic utility. SRA141, a potent, selective, orally bioavailable small molecule inhibitor of cell division cycle 7 kinase (Cdc7). Cdc7 is a key regulator of DNA replication and is involved in the DDR network, making it a compelling emerging target for potential treatment across a broad range of tumor types. An Investigational New Drug Application (IND) submission to the U.S. Food and Drug Administration (FDA) is being prepared in order to commence clinical trials with this drug candidate.
Molecular Insight Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
What if we told you that our bodies make use of only a few hundred different signaling pathways to control all of our 20,000 or so genes. We call it the gene circuitry code, unique for every gene in our body. CAMP4 has built a proprietary 4-D Gene Circuity Platform to codify the discrete set of combinatorial rules used by any human cell type central to disease pathology. By applying the power of computational biology and machine learning algorithms, CAMP4 is able to rapidly solve for druggable targets to control the output of any disease gene of interest.
VGA Billing Services is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.